Effects of resveratrol therapy on glucose metabolism, insulin resistance, inflammation, and renal function in the elderly patients with type 2 diabetes mellitus: A randomized controlled clinical trial protocol

被引:21
作者
Ma, Nan [1 ]
Zhang, Youzhi [2 ]
机构
[1] First Hosp Harbin, Geriatr Ward, 151 Tiandi St, Harbin 150010, Peoples R China
[2] Third Peoples Hosp Sichuan Prov, Dept Emergency, Affiliated Hosp, Sichuan Nursing Vocat Coll, Chengdu, Peoples R China
关键词
blood glucose; inflammation; insulin resistance; nutrient sensing systems; renal function; resveratrol; type 2 diabetes mellitus; SUPPLEMENTATION; MODULATION; EXPRESSION;
D O I
10.1097/MD.0000000000030049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Diabetes mellitus is a spectrum of metabolic disorders characterized by hyperglycemia and shows a growing global public health problem in the elderly. Resveratrol presents antiaging, anti-inflammatory, antitumor antioxidant, and cardioprotective activities. The purpose of this study was to investigate the ameliorative effects of resveratrol on blood glucose, insulin metabolism, lipid profile, renal function, inflammation, and nutrient sensing systems in the elderly patients with type 2 diabetes mellitus. Methods: The study is a single-blind, parallel-group, randomized controlled clinical trial consisting of a 6-month treatment period. A total of 472 elderly patients with type 2 diabetes mellitus were enrolled, and included participants will be randomized into 2 groups: resveratrol (n = 242) and placebo (n = 230). The clinical efficacy and changes in clinical parameters in each group will be measured at the indicated time. Clinical parameters included blood glucose, insulin resistance index, blood lipid index, proinflammatory cytokines, renal function, and nutrient sensing systems. Results: Resveratrol treatment greatly improved glucose metabolism, insulin tolerance, and insulin metabolism compared to placebo. Resveratrol relieved symptoms through enhancing nutrient sensing systems, which in turn reduced production and activity of glucose-6-phosphatase. Compared with placebo, resveratrol treatment significantly decreased proinflammatory cytokines glycated hemoglobin/hemoglobin A1c, interleukin-6, tumor necrosis factor-alpha, and interleukin-1beta in the elderly diabetes. Resveratrol treatment decreased blood glucose parameters, improved the lipid profile (total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides), and renal function compared to placebo. Conclusion: In conclusion, resveratrol treatment improves inflammation, renal function, blood glucose parameters, inflammation, insulin resistance, and nutrient sensing systems in the elderly patients with type 2 diabetes mellitus, indicating resveratrol may be a potential therapeutic drug for the treatment of the elderly patients with type 2 diabetes mellitus.
引用
收藏
页数:8
相关论文
共 28 条
  • [1] Resveratrol: A review of preclinical studies for human cancer prevention
    Athar, Mohammad
    Back, Jung Ho
    Tang, Xmwel
    Kim, Kwang Ho
    Kopelovich, Levy
    Bickers, David R.
    Kim, Arianna L.
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 224 (03) : 274 - 283
  • [2] Diabetes mellitus, metabolic syndrome, and physical activity among Ethiopians: A systematic review
    Bekele, Bayu Begashaw
    Manzar, Md Dilshad
    Alqahtani, Mazen
    Pandi-Perumal, Seithikurippu R.
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2021, 15 (01) : 257 - 265
  • [3] Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus
    Bhatt, Jayesh Kumar
    Thomas, Sabin
    Nanjan, Moola Joghee
    [J]. NUTRITION RESEARCH, 2012, 32 (07) : 537 - 541
  • [4] Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients
    Brasnyo, Pal
    Molnar, Gergo A.
    Mohas, Marton
    Marko, Lajos
    Laczy, Boglarka
    Cseh, Judit
    Mikolas, Esztella
    Szijarto, Istvan Andras
    Merei, Akos
    Halmai, Richard
    Meszaros, Laszlo G.
    Suemegi, Balazs
    Wittmann, Istvan
    [J]. BRITISH JOURNAL OF NUTRITION, 2011, 106 (03) : 383 - 389
  • [5] Novel biomarkers for subtle myocardial involvement in type I diabetes mellitus
    El-Saiedi, Sonia A.
    Hafez, Mona H.
    Sedky, Yasser M.
    Sharaf, Sahar A.
    Kamel, Mona S.
    AbdelMassih, Antoine F.
    [J]. CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM, 2021, 10 (03) : 175 - 181
  • [6] Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
    Frias, Juan P.
    Auerbach, Pernille
    Bajaj, Harpreet S.
    Fukushima, Yasushi
    Lingvay, Ildiko
    Macura, Stanislava
    Sondergaard, Anette L.
    Tankova, Tsvetalina, I
    Tentolouris, Nikolaos
    Buse, John B.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (09) : 563 - 574
  • [7] Resveratrol modulation of signal transduction in apoptosis and cell survival: A mini-review
    Fulda, Simone
    Debatin, Klaus-Michael
    [J]. CANCER DETECTION AND PREVENTION, 2006, 30 (03): : 217 - 223
  • [8] Resveratrol prevents cognitive deficits by attenuating oxidative damage and inflammation in rat model of streptozotocin diabetes induced vascular dementia
    Gocmez, Semil Selcen
    Sahin, Tugce Demirtas
    Yazir, Yusufhan
    Duruksu, Gokhan
    Eraldemir, Fatma Ceyla
    Polat, Selen
    Utkan, Tijen
    [J]. PHYSIOLOGY & BEHAVIOR, 2019, 201 : 198 - 207
  • [9] Effects of Resveratrol in Patients With Type 2 Diabetes Mellitus on Skeletal Muscle SIRT1 Expression and Energy Expenditure
    Goh, Kian Peng
    Lee, Hwei Yee
    Lau, Dawn Pingxi
    Supaat, Wilma
    Chan, Yiong Huak
    Koh, Angela Fang Yung
    [J]. INTERNATIONAL JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM, 2014, 24 (01) : 2 - 13
  • [10] Halushko O, 2020, Georgian Med News, P114